Searched for: in-biosketch:true
person:buyonj01
Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus [Meeting Abstract]
Yip, Kevin; Efuni, Elizaveta; Qian, Yingzhi; Clancy, Robert; Buyon, Jill; Blazer, Ashira
ISI:000507466903173
ISSN: 2326-5191
CID: 4645602
SLE: reconciling heterogeneity
Lockshin, Michael D; Barbhaiya, Medha; Izmirly, Peter; Buyon, Jill P; Crow, Mary K
PMCID:6485210
PMID: 31080630
ISSN: 2053-8790
CID: 3864792
Gerald Weissmann, MD, 1930-2019 In Memoriam [Biography]
Abramson, Steven B.; Cronstein, Bruce; Buyon, Jill P.
ISI:000487786200005
ISSN: 2326-5191
CID: 4354442
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus
Barsalou, Julie; Costedoat-Chalumeau, Nathalie; Berhanu, Adey; Fors-Nieves, Cesar; Shah, Ummara; Brown, Patrick; Laskin, Carl A; Morel, Nathalie; Levesque, Kateri; Buyon, Jill P; Silverman, Earl D; Izmirly, Peter M
OBJECTIVE:Cutaneous neonatal lupus (cNL) occurs in possibly 5%-16% of anti-Ro±anti-La antibody-exposed infants. Data suggest in utero exposure to hydroxychloroquine (HCQ) may prevent cardiac NL. The aim was to assess whether in utero exposure to HCQ decreases the risk of cNL and/or delays onset. METHODS:A multicentre case-control study was performed with 122 cNL cases and 434 controls born to women with a rheumatological disease who had documentation of maternal anti-Ro±anti-La antibodies at pregnancy and confirmation of medication use and the child's outcome. A secondary analysis was performed on 262 cNL cases, irrespective of maternal diagnosis, to determine if HCQ delayed time to cNL onset. RESULTS:Twenty (16%) cNL cases were exposed to HCQ compared with 146 (34%) controls (OR 0.4 (95% CI 0.2 to 0.6); p<0.01). Exposure to HCQ was associated with a reduced risk of cNL; exposure to anti-La antibody and female gender were associated with an increased risk of cNL. Exposure to HCQ remained significantly associated with a reduced cNL risk in the analyses limited to mothers with systemic lupus erythematosus and those who developed rash ≤1 month. When analysing all 262 cNL cases, HCQ-exposed infants were older (6.0 (95% CI 5.7 to 6.3) weeks) at cNL onset versus HCQ-non-exposed infants (4.4 (95% CI 3.9 to 5.0) weeks), but the difference was not statistically significant (p=0.21). CONCLUSION/CONCLUSIONS:Exposure to HCQ was associated with a reduced risk of cNL. Among cNL cases, those exposed to HCQ tend to have later onset of rash. Both findings suggest a protective effect of HCQ on cNL.
PMID: 30297329
ISSN: 1468-2060
CID: 3334702
Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated with Tubulointerstitial Inflammation and Renal Scarring
Jimenez, Alejandra Londono; Mowrey, Wenzhu B; Putterman, Chaim; Buyon, Jill; Goilav, Beatrice; Broder, Anna
OBJECTIVE:To characterize and compare the factors associated with tubulointerstitial inflammation (TII) and tubulointerstitial scarring, defined as interstitial fibrosis and/or tubular atrophy (IF/TA), in patients with lupus nephritis (LN). METHODS:We identified SLE patients with a renal biopsy consistent with LN between 2005 and 2017. Clinical data was collected from the medical records. Multivariable logistic regression models were fitted to assess factors associated with TII and with IF/TA (moderate-to-severe vs. none-or-mild). RESULTS:at the time of biopsy. In addition, the presence of moderate-to-severe TII and older age were also associated with moderate-to-severe IF/TA. None of the routinely available serologic markers, including anti-dsDNA, anti-Ro/La antibodies and low complement were associated with tubulointerstitial damage (TID). CONCLUSIONS:The use of hydroxychloroquine was strongly associated with less inflammation, while the finding of TII, proliferative LN, and low eGFR were the major determinants of the presence of tubulointerstitial scarring. Identifying modifiable factors is critical for the development of better preventive and therapeutic strategies directed towards ultimate improvement in survival in patients with lupus-related kidney disease.
PMID: 29851285
ISSN: 2326-5205
CID: 3137012
Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus [Meeting Abstract]
Buyon, Jill P.; Izmirly, Peter M.; Belmont, H. Michael; Conklin, John; Kaiden, Nicole; Salmon, Jane E.; Alexander, Roberta; Dervieux, Thierry
ISI:000447268903058
ISSN: 2326-5191
CID: 3726262
Pregnancy Outcomes in Mixed Connective Tissue Disease: Results from a Multicentre Cohort Study [Meeting Abstract]
Radin, Massimo; Schreiher, Karen; Jose Cuadrado, Maria; Cecchi, Irene; Andreoli, Laura; Franceschini, Franco; Caleiro, Maria Teresa; Andrade, Danieli; Gibbone, Elena; Khamashta, Munther A.; Buyon, Jill P.; Izmirly, Peter M.; Aguirre, Maria; Benedetto, Chiara; Roccatello, Dario; Marozio, Luca; Sciascia, Savino
ISI:000447268904146
ISSN: 2326-5191
CID: 3726292
Association of the Variant Form of rs17408553 at Human Leukocyte Antigen-C Supports Evidence That Hypo-Responsive Natural Killer Cells Adversely Influence the Course of Nephritis [Meeting Abstract]
Clancy, Robert M.; Belmont, H. Michael; Izmirly, Peter M.; Bornkamp, Nicole; Miller, Sarah; Poulin, Matthew; Yan, Liying; Buyon, Jill P.; Ginzler, Ellen M.
ISI:000447268903322
ISSN: 2326-5191
CID: 3726272
Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms [Meeting Abstract]
Clancy, Robert M.; Langefeld, Carl; Ainsworth, Hannah C.; Belmont, H. Michael; Blaser, Martin; Izmirly, Peter M.; Lacher, Corey; Marion, Miranda C.; Masson, Mala; Silverman, Gregg; Buyon, Jill P.
ISI:000447268902190
ISSN: 2326-5191
CID: 3726282
Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis [Meeting Abstract]
Hartl, Johannes; Clancy, Robert M.; Izmirly, Peter M.; Belmont, H. Michael; Kaiden, Nicole; Bornkamp, Nicole; Sisirak, Vanja; Sally, Benjamin; Buyon, Jill P.; Reizis, Boris
ISI:000447268902185
ISSN: 2326-5191
CID: 3387062